|
(Health-NewsWire.Net, October 20, 2021 )
Market Overview
Genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. For long, patients suffering from disorders and infections related to genitourinary systems have been depending on steroids and immunosuppressant’s which are chemically synthesized and may reciprocate with some serious side effects such as insomnia, acne, nausea, vomiting, and diarrhea. As a result, patients are now turning to biological drugs that not only cause fewer to no side effects but are also more effective in the treatment of genitourinary infections.
View full report: https://www.datamintelligence.com/research-report/genitourinary-drugs-market
Market Dynamics
The global genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, rising disposable incomes, and constant improvements in healthcare infrastructure will drive genitourinary drugs market.
The growing prevalence of genitourinary disorders is expected to drive the market growth
The growing prevalence of genitourinary disorders and the increasing number of pipeline drugs are expected to widen the market growth, globally. In addition, the rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments in R&D activities in developing novel molecules for the treatment of genitourinary diseases, and the increasing number of pipeline drugs are also expected to drive the market, during the forecast period. The vast array of pipeline drugs with a high probability of clearing clinical trials in the future.
For instance, currently, 47 and 16 medications for cervical cancer are in the clinical development phase and phase-II stages respectively, which exemplify the rapidly growing research platform.
The aforementioned factor is believed to be a consequence of collaborative research initiatives conducted by the major pharmaceutical companies consistently striving to strengthen their leadership position in the branded genitourinary drugs market space.
For instance, in September 2016, Bristol-Myers Squibb announced its collaboration with Nektar Therapeutics to evaluate the combined efficacy of NKTR-214 and Opdivo (nivolumab) in treating five tumor types, including bladder cancer. These factors are driving the market growth in the forecast period.
Market Segmentation:
By Disease Type
• Erectile dysfunction
• Gonorrhoea
• Genital Herpes
• Urinary Tract Infections
By Drug Type
• Hormonal Therapy
• Impotence Agents
• Uterine Relaxants
• Miscellaneous Genitourinary Tract Agents
By Distribution Channel
• Hospital Pharmacy
• Pharmacy Stores
• Other
Download free sample: https://www.datamintelligence.com/download-sample/genitourinary-drugs-market
Geographical Analysis
North America region holds the largest market share global genitourinary drugs
North America dominated the market with the largest revenue share in 2020. The rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases and increasing awareness about genitourinary diseases is driving the growth of the market in the region. A quarter to a third of men and women in the U.S. suffer from urinary incontinence. That means millions of Americans.
The prevalence of chronic renal failure is also increasing in the country. For instance, more than 661,000 Americans have renal failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant. The R&D activities related to drug development, adding positive impetus to the demand spurt of genitourinary drugs. Thus the mention factors is driving the growth of the market in the forecast period.
Competitive Landscape
The genitourinary drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Melinta Therapeutics Inc, Cipla USA Inc, Allergan PLC, Merck & Co. Inc., Pfizer Inc., Genentech, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Novartis AG, among others.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of genitourinary drugs globally.
Topic's you may be interested, Artemisinin Combination Therapy Market, Skin and Soft Tissue Infections Market, Intracranial Aneurysm Market, Muscle Stimulator Market, Penicillin Drug Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
